IndraLab

Statements

BAP1 activates Carcinogenesis. 11 / 11
| 11
reach
"PVT1 binding with KLF5 causes KLF5 to stabilise and this elevates the BAP1 levels, which in turn promotes beta-catenin signalling, thus enhancing TNBC carcinogenesis (Li et al., 2018)."
36708551
reach
"Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN."
37543638
reach
"The fact that we determined that highly penetrant, heterozygous pathogenic BAP1 null variants by themselves, as studied by Kadariya et al. , can initiate and drive MM tumorigenesis in mice absent asbestos exposure supports their conclusions, in agreement with Chanock ."
39747518
reach
"BAP1 PGVs accelerate mesothelioma tumorigenesis after asbestos exposure in preclinical models and may be partly predicted by clinical criteria."
37167572
reach
"Besides, a study of families with BAP1 germline mutations shows that mutated BAP1 may promote oncogenesis and increase the risk of KIRC by 8-fold through altering cellular metabolism and the tumor microenvironment (25)."
32944533
reach
"It is expected that BAP1 promotes tumorigenesis of CCA by modulating DNA repair, gene transcription, and post-translational modification, such as glycosylation."
26100596
reach
"42 Other research has speculated that SF3B1 and BAP1 variants can independently lead to oncogenesis and/or malignant progression, reducing the need of their co-occurrence in the natural course of the disease."
40271082
reach
"For instance, in the ~40% of tumors that are seemingly wild-type for both PBRM1 and BAP1, what other events cooperate with VHL loss to promote oncogenesis?"
32947307
reach
"The strongest evidence implicating BAP1 (and PBRM1) in promoting ccRCC tumorigenesis and regulating aggressiveness is provided by genetically engineered mouse models (GEMM)."
35932824
reach
"While RNF2, through H2A monoubiquitination, silences the BCL2 and MCL1 prosurvival genes and thereby induces apoptosis in some cell types, this does not occur in melanocytes, suggesting that BAP1 promotes tumorigenesis in cells that do not engage such RNF2 apoptotic programme.Moving to the p53 tumor suppressor, Karen Vousden (London, UK), who was awarded the CDD Award 2018, retraced the long road leading to her key discoveries of p53 functions."
31641107
reach
"In the context of other genetic backgrounds, the L169P variant could possibly synergize with other oncogenic gene mutation(s), such as BAP1 and p53 uncovered in the highly aggressive and metastatic case of ccRCC [5], to drive tumorigenesis."
37762376